1. Cyhoeddwyd

   Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout

   Hill McManus, D., Marshall, S., Soto, E. & Hughes, D., Medi 2019, Yn: Clinical Pharmacology and Therapeutics. 106, 3, t. 652-660

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   Combining model-based clinical trial simulation, pharmacoeconomics and value of information to optimize trial design

   Hill-McManus, D. & Hughes, D., Ion 2021, Yn: CPT: Pharmacometrics & Systems Pharmacology . 10, 1, t. 75-83 9 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development

   Hill-McManus, D., Marshall, S., Liu, J., Willke, R. & Hughes, D., Gorff 2021, Yn: Clinical Pharmacology and Therapeutics. 110, 1, t. 49-63

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

4. Cyhoeddwyd

   Impact of non-adherence and flare resolution on the cost effectiveness of treatments for gout: Application of a linked pharmacometric/pharmacoeconomic model

   Hill-McManus, D., Marshall, S., Soto, E., Lane, S. & Hughes, D., Rhag 2018, Yn: Value in Health. 21, 12, t. 1373-1381

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data

   Hill-McManus, D. & Hughes, D., Meh 2022, Yn: British Journal of Clinical Pharmacology. 88, 6, t. 2782-2792 11 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   New advice on switching antiepileptic drugs might be a false economy

   Holmes, E. A., Plumpton, C. O., Hughes, D., Holmes, E., Plumpton, C., Duerden, M., Marson, T. & Hughes, D. A., 16 Rhag 2013, Yn: British Medical Journal. 347

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Developing an alternative care pathway for emergency ambulance responses for adults with epilepsy: A Discrete Choice Experiment to understand which configuration service users prefer. Part of the COLLABORATE project

   Holmes, E., Dixon, P., Mathieson, A., Ridsdale, L., Morgan, M., McKinlay, A., Dickson, J., Goodacre, S., Jackson, M., Foster, D., Hardman, K., Bell, S., Marson, A., Hughes, D. & Noble, A. J., Ebr 2024, Yn: Seizure: European Journal of Epilepsy. 118, t. 28-37

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Challenges for economic evaluation of strategies to contain antimicrobial resistance

   Holmes, E. & Hughes, D., 27 Medi 2019, Yn: Antibiotics. 8, 4, 8 t., 166.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Sylw/Dadl › adolygiad gan gymheiriaid

9. Wedi ei Dderbyn / Yn y wasg

   A model-based cost-utility analysis of an automated notification system for deteriorating patients on general wards

   Holmes, E., Hughes, D. & Subbe, C., 18 Ebr 2024, (Wedi ei Dderbyn / Yn y wasg) Yn: PLoS ONE. PONE-D-23-27466R2.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care

    Holmes, E., Harris, S. D., Hughes, A., Craine, N. & Hughes, D., 7 Rhag 2018, Yn: Antibiotics. 7, 4, 19 t., 106.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Patient-focused drug development methods for benefit-risk assessments: A case study using discrete choice experiment for antiepileptic drugs

    Holmes, E. A. F., Plumpton, C., Baker, G. A., Jacoby, A., Ring, A., Williamson, P., Marson, A. & Hughes, D. A., Maw 2019, Yn: Clinical Pharmacology and Therapeutics. 105, 3, t. 672-683 12 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    Predicting Adherence to Medications Using Health Psychology Theories: A Systematic Review of 20 Years of Empirical Research

    Holmes, E. A., Morrison, V. L. & Hughes, D., 8 Rhag 2014, Yn: Value in Health. 17, 8, t. 863-876

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

13. Cyhoeddwyd

    Patient preferences for outcomes in clinical trials: implications for medicines optimization

    Holmes, E., Marson, A. G. & Hughes, D., 8 Mai 2017, Yn: Trials. 18 (Suppl 1), O18, t. 192 1 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Crynodeb Cyfarfod › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    A new taxonomy for describing and defining adherence to medications

    Holmes, E. A., Hughes, D., Morrison, V. L., Vrijens, B., De Geest, S., Hughes, D. A., Prezemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J. K. & Urquhart, J., 1 Mai 2012, Yn: British Journal of Clinical Pharmacology. 73, 5, t. 691-705

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients

    Holmes, E. A., Morrison, V. L. & Hughes, D., Awst 2016, Yn: British Journal of Clinical Pharmacology. 82, 2, t. 522-531

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

18. Cyhoeddwyd

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

19. Cyhoeddwyd

    Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population

    Hughes, D., Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D. A., Baker, G. & Brazier, J., 1 Gorff 2014, Yn: Epilepsy and Behavior. 36, t. 12-17

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

20. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

21. Cyhoeddwyd

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

24. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

26. Cyhoeddwyd

    Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group

    Hughes, D., Linck, P. G., Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F. H., Linck, P. & Cowell, W., 1 Rhag 2013, Yn: Osteoporosis International. 24, 12, t. 2907-2918

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

27. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Gorff 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

28. Cyhoeddwyd

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

29. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

30. Cyhoeddwyd

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 4, t. 315-316

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

32. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn: Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

33. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

34. Cyhoeddwyd

    Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios

    Hughes, D., Parham, P. E. & Hughes, D. A., 16 Chwef 2015, Yn: Philosophical Transactions B: Biological Sciences. 370, 1665

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

35. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

36. Cyhoeddwyd

    The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors

    Hughes, D., Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., Daly, A. K., Aarons, L., Ogungbenro, K., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Ion 2012, Yn: British Journal of Clinical Pharmacology. 73, 1, t. 66-76

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

37. Cyhoeddwyd

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

38. Cyhoeddwyd

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

39. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

40. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

41. Cyhoeddwyd

    Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

    Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Rhag 2012, Yn: Value in Health. 15, 8, t. 1162-1171

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

42. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

43. Cyhoeddwyd

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

44. Cyhoeddwyd

    Understanding medication compliance and persistence from an economics perspective

    Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Ion 2008, Yn: Value in Health. 11, 4, t. 600-610

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

45. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

46. Cyhoeddwyd

    Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity

    Hughes, D., Linley, W. G. & Hughes, D. A., 1 Ebr 2013, Yn: Pharmacoeconomics. 31, 4, t. 345-355

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

47. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

48. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

49. Cyhoeddwyd

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Ion 2013, Yn: Nature Reviews Drug Discovery. 12, 3-4

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

50. Cyhoeddwyd

    Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group

    Hughes, D., Gwadry-Sridhar, F. H., Manias, E., Lal, L., Salas, M., Hughes, D. A., Ratzki-Leewing, A. & Grubisic, M., 1 Gorff 2013, Yn: Value in Health. 16, 5, t. 863-871

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid